Halozyme Therapeutics/$HALO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Halozyme Therapeutics

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Ticker

$HALO
Primary listing

Industry

Biotechnology

Employees

350

ISIN

US40637H1095

HALO Metrics

BasicAdvanced
$7B
15.05
$3.76
1.18
-

What the Analysts think about HALO

Analyst ratings (Buy, Hold, Sell) for Halozyme Therapeutics stock.

Bulls say / Bears say

Halozyme Therapeutics reported a 35% increase in revenue and a 54% growth in net income for Q1 2025, leading to an upward revision of its full-year financial guidance. (Seeking Alpha)
The European Commission approved Bristol Myers Squibb's subcutaneous Opdivo® (nivolumab) co-formulated with Halozyme's ENHANZE® technology for multiple solid tumor indications, potentially expanding Halozyme's market reach. (Halozyme News)
Analysts have set an average 12-month price target of $63.56 for HALO stock, indicating a potential upside of approximately 17.7% from the current price. (Stock Analysis)
Halozyme is engaged in a patent dispute with Merck over the subcutaneous formulation of Keytruda, which could lead to costly litigation and potential revenue loss if the outcome is unfavorable. (Reuters)
The company's total debt stands at $1.54 billion, resulting in a high debt-to-equity ratio of 318.67%, which may raise concerns about financial leverage and risk. (Forbes)
Recent analyst downgrades, such as Morgan Stanley's reduction of the price target from $73 to $62, suggest potential concerns about the company's future performance. (Stock Analysis)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.

HALO Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

HALO Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $HALO

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs